Chemo combo for high-risk blood cancer transplant patients
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a combination of drugs (thiotepa, cyclophosphamide, clarithromycin, and cytarabine) before a stem cell transplant. It is for people with certain types of blood cancer who have responded well to earlier treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of blood cancer confirmed by tests.
- For certain types (Ph+ ALL), your cancer must have no genetic signs after early treatment.
- For other types (Ph- B-ALL), your cancer must have no minimal residual disease after 3 rounds of chemo.
- You must be getting your own stem cells transplanted (autologous transplant).
- You must be 18 to 65 years old.
- You must not have serious heart problems or active infections like HIV, hepatitis B, or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
This trial studies a new way to prepare adults with ALL for a stem cell transplant from a half-matched family donor. It compares two types of radiation-based conditioning to see which works better and has fewer side effects.
This clinical trial tests a new combination of chemotherapy drugs (called TmBU) before a stem cell transplant for people with high-risk or relapsed acute leukemia. The goal is to see if this conditioning regimen works better and is safe for patients who need a transplant.
This study tests a combination of four chemotherapy drugs given before a stem cell transplant to help prepare the body and reduce the chance of lymphoma returning. It is for people with certain types of lymphoma who are scheduled for this transplant.
This trial tests a combination of your own stem cell transplant and a personalized CAR-T cell therapy called CD19-CAR-T. It is for adults with high-risk acute B-lymphoblastic leukemia whose cancer is in remission after initial chemotherapy, and who are able to receive both treatments safely.
This trial tests a stronger chemo and radiation plan before a stem cell transplant for people with myelodysplastic syndrome (a blood disorder) or acute myeloid leukemia (a blood cancer). The goal is to help the transplant work better and reduce the chance of the disease coming back.
Hear when a new Burkitt Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.